Xilio Therapeutics, Inc. (XLO) Return on equity 2024–2025
Xilio Therapeutics, Inc. (XLO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-99.3%FY2025 · since FY2024: -331.0% → -99.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -99.3% | +231.6 pp |
| FY2024 | -331.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice